Gastrointestinal Cancer | Specialty

The gastrointestinal cancer condition center is a comprehensive resource for clinical news and expert insights on gastrointestinal cancer. Read more at OncLive.

Poll: Vote on the Top Gynecologic and GI Cancer Abstracts/Topics to Watch at ESMO 2025

October 6th 2025

Vote on the top abstracts and topics to watch in gynecologic and gastrointestinal oncology during the 2025 ESMO Congress.

Q4 2025: 10 FDA Decisions to Watch in the Realm of Oncology

October 3rd 2025

Here is your Q4 2025 preview spotlighting 10 FDA decisions to watch, including upcoming PDUFAs for belantamab mafodotin, revumenib, sevabertinib, and more.

GPC3 Offers Highly Specific Target in HCC

October 3rd 2025

GPC3 has the potential to be targeted in patients with HCC with reduced off-target toxicities compared with other targeted agents.

OncLive’s September EMA Regulatory Recap: Key EU Approvals in Oncology

October 2nd 2025

Here is your snapshot of all oncologic therapeutic options that were approved by the EMA in September 2025.

Five Under 5: Top Oncology Videos for the Week of 9/21

September 28th 2025

The top 5 OncLive TV videos of the week cover insights in solid tumors, breast cancer, pancreatic cancer, and multiple myeloma.

FDA Grants Utidelone Injection Orphan Drug Designation for Pancreatic Cancer

September 25th 2025

Utidelone injection has received orphan drug designation by the FDA for the treatment of patients with pancreatic cancer.

Dr Shitara on Satri-Cel in Advanced Gastric/GEJ Adenocarcinoma and Pancreatic Cancer

September 24th 2025

Kohei Shitara, MD, discusses efficacy data from a trial of the CAR T-cell therapy satri-cel in advanced gastric/ GEJ adenocarcinoma and pancreatic cancer.

The OncFive: Top Oncology Articles for the Week of 9/14

September 20th 2025

The FDA held a Type A meeting for RP1 in advanced melanoma, the AACR released its Annual Cancer Progress Report, and more.

Retifanlimab Displaces Chemo Alone as the Frontline Standard of Care in SCAC

September 17th 2025

Retifanlimab is the first and only immunotherapy agent to receive an indication for the frontline treatment of patients with advanced SCAC.

KN026 NDA in Pretreated HER2+ Gastric or GEJ Cancer Accepted by NMPA for Review

September 17th 2025

The NDA seeking approval of KN026 plus chemotherapy in HER2-positive gastric or GEJ cancer has been accepted for review in China.

FDA Approval of Belzutifan Provides Needed Option in Pheochromocytoma or Paraganglioma

September 16th 2025

The FDA approval of belzutifan in patients with pheochromocytoma or paraganglioma is a testament to the power of drug discovery in rare tumor subsets.

The OncFive: Top Oncology Articles for the Week of 8/31

September 6th 2025

FDA grants type A meeting to discuss RP1 BLA in melanoma, CBP/p300 bromodomain inhibitor gets fast track status in NSCLC, and more.

Dr Gangaram-Panday on Definitive Chemoradiotherapy in Esophageal Cancer

September 5th 2025

Sanjiv Gangaram-Panday, PhD, discusses findings from a population-based cohort study of definitive chemoradiotherapy in esophageal adenocarcinoma.

Ventana Assay Earns CE IVDR Approval in EU as Companion Diagnostic in HER2-Expressing Breast and Biliary Tract Cancers

September 5th 2025

The VENTANA HER2 (4B5) test earned CE-IVDR approval in Europe to assess HER2 status in metastatic breast cancer and biliary tract cancer.

Dr Shameem on Selecting NALIRIFOX vs FOLFIRINOX in Advanced Pancreatic Cancer

September 3rd 2025

Raji Shameem, MD, discusses considerations for selecting between available chemotherapy regimens for patients with advanced pancreatic cancer.

Dr Klempner on the Safety Profile of Givastomig Plus Nivolumab and mFOLFOX6 in Gastric, Esophageal, and GEJ Cancer

September 3rd 2025

Samuel J. Klempner, MD, details the safety profile of givastomig/nivolumab and mFOLFOX6 in CLDN18.2-positive gastric, esophageal, and GEJ cancers.

OncLive’s August EMA Regulatory Recap: Key EU Approvals in Oncology

September 3rd 2025

Here is your snapshot of all oncologic therapeutic options that were approved by the EMA in August 2025.

Development to Discontinue for ZW171 in Gynecologic, Thoracic, and GI Cancer

September 2nd 2025

The development of ZW171 for gynecologic, thoracic, and GI cancers is being discontinued.

4 Ways Oncologists Use Social Media to Debunk Myths and Dispel Misinformation

August 26th 2025

Eric K. Singhi, MD, and Shruti Patel, MD, discuss how they extend beyond the walls of their clinic to provide accurate cancer updates on social media.

The OncFive: Top Oncology Articles for the Week of 8/17

August 23rd 2025

Adjuvant atezolizumab boosts survival in bladder cancer, FDA clears companion diagnostic for nivolumab doublet in MSI-H/dMMR colorectal cancer, and more.